Cancer Research AACR Conference on Molecular Diagnostics - 2008  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 2476-2482, June 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Contessa, A. R.
Right arrow Articles by Fioretti, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Contessa, A. R.
Right arrow Articles by Fioretti, M. C.

In Vitro Generation of a Highly Immunogenic Subline of L1210 Leukemia following Exposure to 5-(3,3'-Dimethyl-1-triazeno)imidazole-4-carboxamide1

Anna Rita Contessa2, Anna Bonmassar, Antonio Giampietri, Antonella Circolo, Abraham Goldin and Maria Cristina Fioretti

Institute of Pharmacology, University of Perugia, Via del Giochetto, Perugia 06100 Italy [A. R. C., A. B., A. G., A. C., M. C. F.], and National Cancer Institute, NIH, Bethesda, Maryland 20205 [A. G.]

Strong and heritable increase of immunogenicity of L1210 Ha leukemia has been obtained in vitro following multiple treatments with 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC), metabolically activated by mouse liver preparations (MLP) containing liver microsomes. The DTIC-treated leukemia (L1210D line) or the control line treated with MLP alone (L1210N line) showed comparable growth kinetics in vitro. However, progressive increase of immunogenicity occurred in leukemic cells in the course of in vitro treatments with DTIC plus MLP, but not with MLP alone, as evidenced by comparative studies on transplantation immunity elicited in BALB/c x DBA/2 F1 mice by graded inocula of L1210D or L1210N leukemia cells. In vivo experiments confirmed that metabolic transformation of DTIC is required for increasing tumor immunogenicity. In fact, L1210Ha cells became highly immunogenic when treated with DTIC in intact mice but not in animals metabolically depressed by CCI4. Immunochemotherapy experiments based on the antigenic cross-reactivity between the L1210D line and the original L1210Ha leukemia showed that i.p. administration of L1210D cells followed by 1,3-bis(2-chloroethyl)-1-nitrosourea treatment afforded marked protection in mice inoculated intracerebrally with the parental lymphoma.

The present findings could provide an adequate in vitro technique for developing further studies on DTIC-mediated immunogenic changes of tumors, including human cancer cells growing in tissue culture.

1 This work was supported by a C.N.R. (Rome, Italy) contract: Progetto Finalizzato Controllo della Crescita Neoplastica, Sottoprogetto: Controllo Çhemioterapico N.80.01521.96.

2 To whom requests for reprints should be addressed.

Received 4/ 1/80. Accepted 2/ 5/81.




This article has been cited by other articles:


Home page
JCOHome page
M. S. Mitchell
Chemotherapy for Melanoma: The Resultant of Conflicting Vectors
J. Clin. Oncol., June 1, 2004; 22(11): 2043 - 2045.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.